Abstract
Introduction

40
Modern agricultural practices strongly rely on the use of plant protection chemicals that can provide the 41 required crop yields in order to feed an ever-growing human population with high quality and inexpensive 42 foods. Even though pesticides are usually applied according to the rules of Good Agricultural Practices, 43 residues are regularly detected in agricultural commodities and in aquatic environments. The presence of 44 trace amounts of this sort of xenobiotics might result in adverse consequences to humans and to non-45 target organisms. Hence, these substances need to be strictly controlled to safeguard human health and to 46 protect the environment. In addition, the presence of multiple pesticide residues, even at low 47 6
The aqueous layer was reserved and the combined organic layers were washed with brine and dried over 138 anhydrous Na 2 SO 4 . Filtration and evaporation of the solvent under reduced pressure afforded a solid 139 corresponding to unreacted azoxystrobin (210 mg, 41%). The aqueous phase was cooled in an ice bath and 140 acidified with stirring to pH 3 by the addition of solid KHSO 4 . The resulting yellow suspension was extracted 141 with ethyl ether and the combined organic layers were washed with brine and dried over anhydrous 142 Na 2 SO 4 . The residue remaining after evaporation of the solvent was purified by chromatography, using 143 mixtures of increasing polarity of CHCl 3 -MeOH (from 99:1 to 90:10) as eluent, to give, in order of elution, 144 AZ-enol (3, 198 mg) as a yellowish oil and AZ-acid (2, 43 mg) as a white solid (mp 85-87 °C crystallized from 145 CH 2 Cl 2 -hexane). These amounts correspond to yields of 68% and 15%, respectively, based on recovered 146 starting material. 147 148
Preparation of (Z)-Methyl 2-(2-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)phenyl)-3-methoxyacrylate 149 (AZ-Z, 5) 150
The photoisomerization product of azoxystrobin, Z-stereoisomer 5, was prepared from azoxystrobin (1) 151 as shown in Fig. 1A following a reported procedure (Clough et al., 1992) . Spectroscopic data, not previously 152 described in the literature, allowing a complete and unequivocal structural characterization of this 153 compound are given in the Supplementary Data File. 154 155
Preparation of 2-(6-hydroxypyrimidin-4-yloxy)benzonitrile (AZ-pyOH, 8) 156
Synthesis of 4-tert-butoxy-6-chloropyrimidine (6) 157
A 1 M solution of potassium tert-butoxide in tetrahidrofuran (THF) was dropwise added (2.18 mL, 2.18 158 mmol) under nitrogen into a solution of 4,6-dichloropyrimidine (325.7 mg, 2.18 mmol) in anhydrous THF 159 cooled to 0 °C (Fig. 1B) . The resulting orange mixture was stirred at 0 °C for 90 min, then poured into water 160 and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous 161 Na 2 SO 4 . The solvent was carefully eliminated in the rotavapor (the compound formed is relatively volatile), 162 and the residue left was purified by chromatography, using hexane-EtOAc 9:1 as eluent, to give the tert-163 butoxypyrimidine 6 (315 mg, 75%) as a colorless oil. 164
Synthesis of 2-(6-tert-butoxypyrimidin-4-yloxy)benzonitrile (7) 166
Anhydrous N,N-dimethylformamide (DMF, 2.5 mL) was added to a mixture of tert-butoxypyrimidine 6 167 (123.5 mg, 0.662 mmol), 2-cyanophenol (94.63 mg, 0.794 mmol), and Cs 2 CO 3 (323.53 mg, 0.993 mmol) 168 under nitrogen. The mixture was stirred at 110 °C for 18 h, then cooled to rt, poured into water, and 169 extracted with EtOAc. The organic layer was washed consecutively with 10% aqueous NaOH, water, and 170 brine and dried over anhydrous Na 2 SO 4 . Evaporation of the solvent afforded compound 7 (166 mg, 99%) as 171 a white solid (mp 88-90 °C crystallized from CH 2 Cl 2 -hexane) that was pure enough, as judged by 1 H NMR, 172 to be used in the next step without further purification. 173 174
Synthesis of 2-(6-hydroxypyrimidin-4-yloxy)benzonitrile (8) 175
Trifluoroacetic acid (1 mL) was dropwise added under nitrogen to a stirred solution of tert-176 butoxypyrimidine 7 (57.3 mg, 0.212 mmol) in anhydrous CH 2 Cl 2 (1 mL) cooled at 0 °C ( 
Preparation of 2-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)benzoic acid (AZ-benzoic, 11) 182
Synthesis of 2-(6-chloropyrimidin-4-yloxy)benzonitrile (9) 183
A mixture of 2-cyanophenol (262 mg, 2.19 mmol), 4,6-dichloropyrimidine (326 mg, 2.19 mmol), and 184 Cs 2 CO 3 (1.07 g, 3.29 mmol) in anhydrous DMF (7.5 mL) was stirred at rt under nitrogen for 3 h. The mixture 185 was poured into water, extracted with EtOAc, and the combined extracts washed with brine, dried over 186 anhydrous Na 2 SO 4 , and concentrated under vacuum to leave a yellowish oil of nearly pure compound 9 187 (505 mg, 99%), which was used in the next step without further purification. 188
Synthesis of methyl 2-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)benzoate (10) 189
A solution of the chloropyrimidine 9 (91.2 mg, 0.393 mmol), methyl salicilate (92.7 mg, 0.609 mmol), 190
and Cs 2 CO 3 (256 mg, 0.786 mmol) in anhydrous DMF (2 mL) was stirred at 100 °C for 90 min under nitrogen. 191
The mixture was cooled to rt, poured into water and extracted with EtOAc. isopropanol (0.75 mL) and water (0.68 mL) was stirred at rt for 45 min (Fig. 1B) Ninety-six-well polystyrene ELISA plates were coated by overnight incubation at rt with 100 µL solutions of 207 OVA-hapten conjugates. Coated plates were washed four times with washing solution and received, 208 afterwards, 50 µL per well of analyte standard (or metabolite) in PBS plus 50 µL per well of mAb solution in 209 PBST. After 1 h at rt of immunological reaction, plates were washed as described before. Next, 100 µL per 210 well of a 1/2000 dilution of RAM-HRP conjugate in PBST was added and incubated again 1 h at rt. After 211 washing, the signal was obtained by addition of 100 µL per well of freshly prepared 2 mg/mL 212 o-phenylenediamine solution containing 0.012% (v/v) H 2 O 2 in enzyme substrate buffer. The enzymatic 213 reaction was stopped after 10 min at rt with 100 µL per well of 2.5 M sulfuric acid. The absorbance was 214 immediately read at 492 nm with a reference wavelength at 650 nm. 215
Standards and data treatment 216
Eight-point standard curves of azoxystrobin and transformation products were prepared from 217 concentrated stock solutions in anhydrous DMF by serial dilution in PBS, including a blank point. 218
Experimental values were fitted to a four-parameter logistic equation using the SigmaPlot software package 219 from SPSS Inc. (Chicago, IL, USA). Assay sensitivity was defined as the concentration of analyte at the 220 inflection point of the fitted curve, typically corresponding to a 50% inhibition (IC 50 ) of the maximum 221 absorbance (A max ) if the background signal approaches to zero. Cross-reactivity was calculated as the 222 percentage of the ratio between the IC 50 value for azoxystrobin and the IC 50 value for the corresponding 223 transformation product. 224
Buffer studies 225
The influence of ionic strength, pH, and Tween 20 concentration over the antibody-antigen interaction 226 was evaluated following a multiparametric approach. The selected model was based on a central composite 227
design. Briefly, a full factorial design was performed with 3 factors that included 8 cube, 6 axial, and 6 228 central points, with 3 replicates each located at random positions, involving a total of 15 buffers. Ionic 229 strength values ranging from 50 to 300 mM, pH values from 5.5 to 9.5, and Tween 20 concentrations from 230 0.00 to 0.05% (v/v) were used as axial points. Buffer characteristics used in this study are shown in Table S1 231 of the Supplementary Data File and they were prepared as follows. First, a 40 mM trisodium citrate, 40 mM 232 disodium hydrogen phosphate, and 40 mM Tris solution (pH 9.9) was prepared, and known volumes of 5 M 233
HCl were added in order to achieve the desired pH in each case. Then, the ionic strength of each solution 234 was calculated, considering the initial solution and the employed volume of HCl, and the appropriate 235 volume of a 2 M NaCl solution was added to every buffer aliquot in order to achieve the required ionic 236 strength. Finally, Tween 20 was included at the corresponding concentration before the final volume was 237 achieved by addition of deionized water. The concentration of Tween 20 and the ionic strength of the 238 buffers were twice the final values in the assays. For the evaluated antibody (mAb AZa6#210), OVA-hapten 239 coated microplates were prepared (OVA-AZa6 at 0.1 µg/mL) and cELISAs were carried out using 240 azoxystrobin standard curves in water, whereas mAb solutions (80 ng/mL) were prepared in every 241 evaluated buffer. Changes in the inhibition curve parameters were fitted by a multiple regression equation, 242 including curvature and interaction terms, using Minitab 14.1 software (Minitab Inc., State College, PA, 243 USA). 244
Results and discussion
245
Preparation of azoxystrobin transformation products 246
The major metabolite and degradation compound of azoxystrobin in aerobic soils, anaerobic soils, and 247 water-sediment systems was reported to result from hydrolysis of the methyl ester moiety to form the 248 Based on those precedents, relevant azoxystrobin transformation products intended for antibody 266 recognition studies were prepared from readily available starting materials. Compounds 2, 3, and 5, which 267 preserve most of the molecular framework, were obtained from technical-grade fungicide (Fig. 1A) . The 268 preparation of AZ-acid (2), the major metabolite of azoxystrobin, was more difficult than initially expected. Supplementary Data File). As a result, the most abundant hydrolytic compound was unambiguously 281 identified as the AZ-enol 3 (68% yield based on recovered unreacted starting material) while the other 282 substance could be identified as the acid metabolite 2 (15% yield). The preference for the formation of the 283 enol derivative under basic hydrolysis conditions was also confirmed with picoxystrobin, a strobiluring 284 fungicide bearing in its structure the same methyl β-methoxyacrylate moiety than azoxystrobin (Parra et 285 al., 2011b). Finally, it is worthy to note that enol 3 exists, at least in CDCl 3 solution, with the (Z)-geometry of 286 the double bond, which seems to be stabilized by formation of an intramolecular hydrogen bond between 287 the hydroxyl proton and the carbonyl oxygen.
The synthesis of the azoxystrobin photoproduct, the (Z)-isomer 5, was also accomplished from 289 azoxystrobin (Fig. 1A) following a literature procedure (Clough et al., 1992) . This strategy involved the 290 oxidative cleavage of the acrylate double bond to give keto-ester 4, from which the methoxymethylene 291 moiety was regenerated by means of a Wittig reaction. The last reaction is not stereoselective, leading to a 292 nearly equimolecular mixture of (E)-and (Z)-isomers, from which compound 5 could be separated, in about 293 22% yield based on recovered starting material, and spectroscopically characterized. 294
The synthesis of the two other intended transformation products of azoxystrobin (compounds 8 and 11) 295 was undertaken starting from 4,6-dichloropyrimidine ( attempts to directly introduce the hydroxyl group failed, so it was incorporated in the form of a tert-298 butoxide group and ultimately released in due course by acid hydrolysis. Thus, treatment of 299 4,6-dichloropyrimidine with an equivalent of potassium tert-butoxide in THF at rt (Kofink and Knochel, 300
2006) afforded the tert-butoxide derivative 6, which was subjected to another nucleophilic substitution 301 reaction of the chlorine atom with 2-cyanophenol, using in this case more vigorous conditions, to give 7. 302
The final step that led to pyrimidinol 8 involved acid-promoted cleavage of the tert-butyl ether moiety, 303 which took place very efficiently by treatment of intermediate 7 with trifluoracetic acid at rt. The synthesis 304 of the benzoic acid derivative 11 was achieved, as before, through two consecutive nucleophilic aromatic 305 substitution reactions. First, 4,6-dichloropyrimidine was reacted under very smooth basic conditions with 306 2-cyanophenol to afford pyrimidinyl-aryl ether 9, which then reacted with methyl 2-hydroxybenzoate to 307
give compound 10 under conditions similar to those previously used for the transformation of 6 into 7. 308
Finally, base-catalyzed hydrolysis of the methyl ester moiety of 10 provided AZ-benzoic (11) in very high 309 overall yield from 4,6-dichloropyrimidine. 310
All the synthesized products were characterized using widely available instrumentation instead of 311 sophisticated equipment in order to facilitate the identification of azoxystrobin transformation products 312 under less demanding situations. To this purpose, degradates were analyzed by HPLC-DAD employing two 313 different gradient systems, i.e., mixtures of MeOH-H 2 O and MeCN-H 2 O (Table 1) . Under both conditions, 314 the two azoxystrobin stereoisomers eluted with clearly different retention times. However, none of the 315 assayed eluents was able to properly resolve the structural isomers AZ-acid and AZ-enol; indeed, with 316 mixtures of MeCN-H 2 O also AZ-benzoic coeluted with AZ-acid and AZ-enol. On the other hand, with the 317
MeOH-H 2 O gradient, AZ-benzoic separated from these two isomers but coeluted with AZ-pyOH. These 318 results emphasize the actual complexity of distinguishing between AZ-acid and AZ-enol, given their similar 319 chromatographic behaviour and identical mass. Fortunately, all five transformation products migrated 320 separately by TLC using a CHCl 3 -MeOH mixture (98:2, v/v). As a matter of fact, AZ-acid and AZ-enol clearly 321 separated from each other by TLC (Rf values of 0.21 and 0.68, respectively), which makes this analyticalprocedure a simple method to differentiate between these two azoxystrobin degradates (Table 1) . The 323 product with the lowest Rf value (0.10) was AZ-benzoic. This result contrasts with that obtained by Singh et 324 al. (2010), who reported an Rf value for AZ-benzoic of 0.62, higher than the value they gave for AZ-acid 325 (0.175) and very similar to that of azoxystrobin itself (0.71). 326
Recognition of azoxystrobin transformation products by a collection of mAbs 327
Antibodies are binding biomolecules most often exhibiting outstanding specificity to their target 328
antigen. In the case of mAbs against low molecular mass analytes, the recognition profile to structurally 329 related compounds is however greatly influenced by the structure of the immunizing hapten (Suárez-330
Pantaleón et al., 2011). With this idea in mind, we decided to test a collection of anti-azoxystrobin mAbs for 331 their ability to also recognize, with high affinity, the transformation products described above. The assayed 332 panel of mAbs was produced in our laboratory following standard cell culture techniques from mice 333 immunized with haptens bearing, as reactive chemical group for protein coupling, a carboxylic linker 334 tethered at different positions of the azoxystrobin molecular framework (Fig. S1) . 335
The binding properties of our antibody library were examined by performing inhibition experiments in 336 the homologous indirect cELISA format with standard solutions of the azoxystrobin transformation 337 products (from 10 5 to 10 −2 nM, plus a blank). First, competitive checkerboard experiments were run in 338 order to determine the adequate concentration of each immunoreagent combination for an optimal 339 competition. Our aim was to identify an antibody capable of equally recognizing azoxystrobin and most of 340 its breakdown compounds. To this purpose, IC 50 values for each mAb/degradate pair were obtained and 341 used to calculate cross-reactivities as described in the Materials and Methods section (Table 2) . Not 342 surprisingly, no mAb was able to noticeably recognize AZ-pyOH, most likely because this compound lacks 343 one of the three aromatic rings that constitute the whole azoxystrobin molecule. Similarly, most mAbs did 344 not bind AZ-benzoic, thus emphasizing the importance of the acrylate moiety in the antibody interaction 345 with the fungicide. Only two mAbs, AZa6#26 and AZa6#210, bound this degradate to a slight degree (4.69% 346 and 6.19%, respectively). Concerning recognition of compounds AZ-Z, AZ-acid, and AZ-enol, several mAbs 347 could clearly accommodate them at their binding sites. These antibodies were mainly found among those 348 sets deriving from immunizing haptens AZa6 and AZc6 (Fig. S1 ). In particular, five out of eight mAbs from 349 these two groups bound AZ-Z with sound affinity. This result is particularly relevant because both was also the case of AZ-enol, which was recognized even better than AZ-Z (CR = 25-85%). In fact, the IC 50values for these three compounds with mAbs AZa6#26, AZa6#210, and AZa6#31 were around 1 nM, a 356 remarkable affinity for such small organic chemicals. The most notable antibody was mAb AZa6#210, which 357 displayed the highest recognition for AZ-acid and AZ-enol, and almost the same affinity towards the two 358 azoxystrobin estereoisomers (see Fig. 3 for a visual comparison with a more specific antibody). Accordingly, 359 this mAb was the subject of further studies. (Fig. 4) , a wide area of pH and ionic strength 377 variations was clearly defined in which changes in those parameters remained tolerable; that is, between 378 80 and 120%. A low dependence on the ionic strength conditions was revealed, whereas assay sensitivity 379 slightly decreased at acidic pHs. Therefore, mAb AZa6#210 withstands modifications in the immunoreaction 380 conditions, so it is a suitable candidate for the development of generic competitive immunoassays adapted 381 to the analysis of azoxystrobin residues. If acidic samples were to be analyzed, assays could be run in 100 382 mM phosphate, pH between 7.5 and 8.0, together with Tween 20 at a usual concentration (0.025%). 383 384
Analysis of mixtures of azoxystrobin stereoisomers 385
As a proof-of-concept for the development of a generic rapid immunochemical assay, mixtures of 386 azoxystrobin and AZ-Z in water were determined by cELISA using mAb AZa6#210 as bioreceptor. For 387 comparison, the same samples were simultaneously determined using mAb AZo6#49, an antibody that 388 displayed a CR value for AZ-Z of just 1%. Deionized water aliquots were spiked with the same total amount 389 of fungicide (1000 ng mL −1 ) but at different proportions of the two isomers. When the sample just 390 contained AZ-Z (Fig. 5, mixture A) , only the mAb AZa6#210 was able to detect the analyte. Otherwise, in 391 samples containing 100% azoxystrobin (E isomer) the same experimental concentration was obtained with 392 both antibodies (Fig. 5, mixture G) . Briefly, a clearly different output was obtained by both antibodies in 393 mixtures containing less than 75% of AZ-E. This simple experiment clearly proved the feasibility of mAb 394 AZa6#210 to determine samples containing both stereoisomers as a whole, which is a requirement in some 395 international regulations. 396
In summary, five relevant azoxystrobin transformation products were synthesized and characterized in 397 detail by a number of different techniques, including MS, NMR, IR, HPLC-DAD, and TLC. With these 398 degradates available, a collection of mAbs derived from haptens functionalized at selected sites was 399 screened in order to find binders able to recognize the synthesized compounds. This approach allowed us 400 to identify a mAb (AZa6#210) displaying high affinity values to azoxystrobin and to three important 401 breakdown products; that is, AZ-Z, AZ-enol, and AZ-acid. The described antibody could be considered as a 402 azoxystrobin (E isomer) in each mixture was: A, 0%; B, 10%; C, 25%; D, 50%; E, 75%; F, 90%; G, 100%. 514 a Values correspond to cross-reactivities referred to the IC50 (nM) of azoxystrobin, which is considered 100%. Assays were carried out in the homologous indirect cELISA format, using for every combination of mAb and conjugate those concentrations resulting in the lowest IC50 value for azoxystrobin with an Amax higher than 1.0. Table 2 Figure 1 Synthes¡s of azorystrob¡n transformation products and selection of monoclonal antibod¡es for ¡mmunoassay development Declarat¡ons Toxicology Leúters requires that all authors sign a declarat¡on of conf¡cting interests. ¡f you have nothing to declare ¡n any of these categor¡es then this should be stated.
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